Core Insights - Investors often focus on the price-to-earnings (P/E) ratio for stock valuation, but it has limitations [1] - The EV-to-EBITDA ratio is considered a more comprehensive valuation metric, providing a clearer picture of a company's true value and earnings potential [2][4] Valuation Metrics - EV-to-EBITDA is calculated by dividing a company's enterprise value (EV) by its earnings before interest, taxes, depreciation, and amortization (EBITDA) [4] - EV accounts for market capitalization, debt, and preferred stock, minus cash and cash equivalents, offering a complete view of a company's value [4] - EBITDA provides insight into profitability by excluding non-cash expenses, making it a useful proxy for cash flows [4] Investment Opportunities - Stocks with low EV-to-EBITDA ratios are often seen as undervalued and attractive for acquisition [5] - Companies like Astrana Health, KT Corporation, Upbound Group, Noah Holdings, and DXP Enterprises have impressive EV-to-EBITDA ratios, indicating potential investment opportunities [3][9] Screening Criteria for Bargain Stocks - Parameters for screening include EV-to-EBITDA less than the industry median, P/E less than the industry median, and P/B less than the industry median [8][10] - Additional criteria include a minimum average trading volume, current price above $5, and a favorable Zacks Rank [11] Company Profiles - Astrana Health is a physician-centric healthcare company with a Zacks Rank of 1 and an expected earnings growth rate of 76.7% for 2025 [12][13] - KT Corporation, the largest telecommunications operator in South Korea, has a Zacks Rank of 2 and an expected earnings growth rate of 280% for 2025 [13] - Upbound Group, a lease-to-own provider, has a Zacks Rank of 2 with a projected earnings growth rate of 9.1% for 2025 [14] - Noah Holdings, a wealth management service provider in China, has a Zacks Rank of 2 and an expected earnings growth rate of 28% for 2025 [15] - DXP Enterprises, providing innovative solutions and services, has a Zacks Rank of 2 and an expected earnings growth rate of 17.5% for 2025 [16]

Core Viewpoint - Tesla's true value may lie in its future product platforms, such as autonomous robotaxis and humanoid robots, rather than its current electric vehicle (EV) sales [1][10] Sales Performance - Tesla delivered 1.79 million EVs in 2024, marking a 1% decline from the previous year, which is the first annual drop since 2011 [5] - In Q1 2025, Tesla delivered 336,681 EVs, reflecting a 13% year-over-year decline [6] - For Q2 2025, Tesla delivered 384,122 EVs, also down 13% year-over-year, indicating a potential sharper annual decline in sales for 2025 compared to 2024 [6] Competitive Landscape - Tesla's sales in Europe fell by 40% in May, while the overall EV market in Europe grew by 26% [7] - Chinese EV brands have doubled their market share in Europe, presenting significant competition for Tesla [7] - Tesla's pricing strategy is challenged by competitors like BYD, which offers lower-priced models, making it difficult for Tesla to compete in key markets [8] Future Product Development - Tesla is focusing on its Cybercab robotaxi, which will operate on full self-driving software, avoiding a price war with competitors [9][10] - The goal is to have millions of Cybercabs generating revenue through passenger transport and small deliveries [10] Financial Implications - Tesla's total revenue shrank by 9% in Q1 2025, with earnings plummeting by 71% to $0.12 per share [13] - The stock is down approximately 34% from its peak, but the decline in earnings is more severe, leading to a high price-to-earnings (P/E) ratio of 173.4 [14] - Comparatively, major tech companies have an average P/E ratio of 35.4, indicating Tesla's stock may be overvalued [15] Market Outlook - If Tesla's FSD and Cybercab initiatives succeed, the current stock price may appear cheap in the long term, but regulatory hurdles remain [16] - Significant declines in stock value could occur if EV sales continue to drop or if the robotaxi business fails to gain traction [18]

Key Takeaways CMA stock rose 21.2% in a year, outpacing its industry and signaling strong investor confidence. Comerica cut non-interest expenses and improved efficiency, with a Q1 ratio drop from 76.91% to 70.28%. Strong NII growth, solid liquidity, and shareholder payouts highlight Comerica's financial resilience.Comerica Incorporated (CMA) shares have gained 21.2% over the past year, outperforming the industry’s rise of 19.5%. Its peers, Northern Trust Corporation (NTRS) and BankUnited Inc. (BKU) , hav ...

Company Overview - Ford is currently outperforming the broader market, with its stock up nearly 3% in 2025, despite a poor long-term track record [1] - The stock is trading below $11, raising questions about whether it is a good buying opportunity for long-term investors [2] Economic Moat - Ford lacks a significant economic moat, as evidenced by a return on invested capital (ROIC) of 8.6%, which is below the desirable threshold of over 20% [5] - The competitive landscape in the auto industry is fierce, with both domestic and foreign automakers competing for market share, further complicating Ford's position [6] Industry Context - The auto industry is mature, with Ford's total revenue in 2024 reaching $185 billion, only 28% higher than a decade ago [9] - The number of cars sold in the U.S. remains stagnant, with 17.8 million cars sold in April, the same as 25 years ago, indicating limited growth potential [9] Growth Opportunities - Ford's Pro segment, focused on commercial operations, showed a promising 15% sales growth in 2024, with an operating margin of 13.5% [10] Valuation - Ford's stock is considered cheap, trading at a price-to-earnings (P/E) ratio of 8.1, significantly lower than the overall market, and offering a dividend yield of 5.9% [11] - However, due to the capital-intensive and cyclical nature of its operations, Ford may not achieve a market-aligned multiple, and the dividend could be at risk during economic downturns [12]

Griffon Corporation (GFF) shares have dropped 19.5% in the past six months, wider than the industry and the S&P 500’s decline of 6.1% and 3.2%, respectively. The company’s performance is also notably weaker than its peers, 3M Company (MMM) and Carlisle Companies Incorporated (CSL) , which have gained 11.4% and lost 15.5%, respectively, over the same time frame.GFF’s Six-Month Price PerformanceImage Source: Zacks Investment ResearchClosing at $67.20 in the last trading session, the stock is trading much belo ...

Core Insights - Keurig Dr Pepper Inc. (KDP) is currently undervalued with a forward 12-month P/E ratio of 16.04X, lower than the industry average of 18.31X and the sector average of 17.39X [1][4] - KDP shares have appreciated 5.9% in the last three months, outperforming the Zacks Beverages - Soft Drinks industry's growth of 1% and the broader Consumer Staples industry's return of 3.5% [4] Valuation Picture - The stock offers compelling value to investors seeking exposure to the consumer staple sector [4] Performance Analysis - KDP's strong performance in Q1 2025 is attributed to its consumer-focused innovation model, which has driven market share gains in key categories such as liquid refreshment beverages, K-Cup pods, and brewers [6][10] - The company achieved a 4.8% year-over-year increase in net sales, or 6.4% on a constant-currency basis, in Q1 2025, with a 3.6% rise in volume/mix and a 2.8% benefit from favorable pricing [10] Segment Growth - The U.S. Refreshment Beverages segment saw sales reach $2.32 billion in Q1 2024, marking an 11% year-over-year increase, supported by an 8% rise in volume/mix and a 3% increase in net price realization [11] - Strong performance in liquid refreshment beverages was driven by brands like Peñafiel and core offerings such as Dr Pepper and Crush, with the acquisition of GHOST enhancing the energy drink portfolio [12] Future Outlook - The Zacks Consensus Estimate for KDP's 2025 earnings has increased by a penny in the past 30 days, indicating positive sentiment [13] - For 2025, the consensus estimates imply 5.61% and 6.25% year-over-year growth in sales and EPS, respectively [13] Strategic Initiatives - KDP's growth reflects a strategic combination of innovation, brand activity, and strong commercial execution, with a focus on cost efficiency and disciplined capital management [7] - The company has strengthened its distribution network with new territory expansion in Tennessee and enhanced its Direct Store Delivery network in Mexico [9]

The Coca-Cola Company (KO) stock recently slipped below its 50-day simple moving average (SMA), indicating a potential short-term bearish trend. Yesterday, KO stock closed at $69.53, staying below the 50-day SMA of $70.88. The stock of this beverage behemoth has been witnessing a significant downtrend in the past month, which resulted in a fall below the 50-day SMA on May 9, 2025. Since then, KO stock has been on a downtrend. Notably, KO stock has declined 3.9% since reporting earnings on April 29, 2025.Coc ...

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock's current market price does not adequately reflect its higher earnings, it suggests potential for growth.But there is more to this whole P/E story. Because not only low P/E, stocks with a rising P/E can also fetch strong returns. In this re ...

Core Insights - Pfizer (PFE) shares increased by 3% following the release of Q1 earnings that significantly exceeded expectations, although the stock has declined 10% year-to-date [1][6] - The company is trading near multi-year lows at approximately $20 per share, which may attract investors looking for a rebound [2][6] Q1 Results - Pfizer reported Q1 earnings of $0.92 per share, surpassing EPS expectations of $0.64 by 43% and up from $0.82 in the same quarter last year [3][4] - Q1 sales totaled $13.71 billion, falling short of estimates of $13.83 billion and down from $14.87 billion year-over-year [4] Full-Year Guidance - Pfizer reaffirmed its fiscal 2025 guidance, projecting revenues between $61 billion and $64 billion, with Zacks projections at $63.48 billion [7] - The company expects adjusted FY25 EPS to be in the range of $2.80 to $3.00, with the Zacks Consensus at $2.99 [7] Valuation Metrics - Pfizer's stock is trading at a price-to-forward earnings ratio of 7.7X, significantly lower than its decade-high of 20.1X and below the S&P 500's 21.3X [8] - The stock is also trading at a discount compared to the Zacks industry average of 16.4X [8] Dividend Information - Pfizer offers an annual dividend yield of 7.46%, which is substantially higher than the industry average of 2.51% and the benchmark's 1.33% [10] - The company has increased its dividend for 16 consecutive years, despite losing its dividend aristocrat status during the 2008 financial crisis [10] Market Sentiment - Following the Q1 report, Pfizer holds a Zacks Rank 2 (Buy), with earnings estimate revisions for FY25 and FY26 trending upward [12] - The company's strong performance in exceeding EPS expectations and its cost-saving initiatives may enhance its valuation and attract long-term investors [13]

Like an open can of soda left out overnight, PepsiCo (PEP -3.18%) stock has lost its fizz lately -- it's down by about 15% over the past year at the time of this writing. Though it has delivered consistent earnings growth, the combination of muted guidance for the year ahead and rising uncertainties about the outlook for the U.S. economy are weighing on the beverages and packaged foods giant.Does the stock's current weakness point to more downside ahead, or are there good reasons for investors to stay optim ...